Alexion Pharmaceuticals has acquired Taligen Therapeutics, a privately held development-stage biotechnology company based in Cambridge, MA. The $111 million acquisition broadens Alexion’s portfolio of product candidates and expands Alexion’s capabilities in translational medicine by bringing in additional researchers. Taligen has a number of preclinical compounds, including potential treatments for patients with ophthalmic diseases such as age-related macular degeneration (AMD), as well as other...